Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibiotic combo takes on deadly hospital pneumonia

NCT ID NCT07327619

Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests a new antibiotic combination (meropenem and pralurbactam) against an existing one (ceftazidime and avibactam) for treating hospital-acquired and ventilator-associated bacterial pneumonia. About 420 adults will participate, and the main goal is to see if the new drug is at least as good at preventing death within 14 days. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Meropenem and pralurbactam (antibiotic combination)
What this could lead to
If it works, this could provide a new treatment option for serious hospital-acquired pneumonia, potentially saving lives.
What could go wrong
This is a phase 3 trial, but it's testing non-inferiority, not superiority, so the new drug may not be better than existing options. Side effects and antibiotic resistance are possible risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 420 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Male or female participants ≥18 and ≤80 years of age 2\. have a diagnosis of HAP/VAP. 3\. have systemic signs and respiratory signs or symptoms of HAP/VAP. 4\. New or worsening infiltrate on chest X-ray/CT obtained within 48 hours prior to screening. 5\. The estimated survival time is at lest 28 days. Exclusion Criteria: * 1\. Diagnosed or suspected CAP, Atypical pneumonias, Viral pneumonia or Chemical pneumonia. 2\. The total duration of antibiotic exposure for antibiotics whose administration begins in the 72 hours is longer than 24 hours. 3\. Acute Physiology and Chronic Health Evaluation (APACHE) II score \>30. 4\. Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials. 5\. Those who have a history of drug abuse or drug abuse within 6 months before screening. 6\. Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hospital-acquired bacterial pneumonia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nosocomial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hunan University Of Medicine General Hospital

    RECRUITING

    Huaihua, Hunan, 418000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.